?Natural birth? for diabetic mother
Norwich University Hospital has its own newborn announcement
Norwich University Hospital has its own newborn announcement
Cardiologists at The Mount Sinai Hospital have begun implanting tiny, state-of-the-art microchip sensors in patients with advanced heart failure to better monitor symptoms and reduce their chances of returning to the hospital.
The implantable sensor, called the CardioMEMS HF System, developed by St. Jude Medical, is a battery-less, dime-sized device placed directly inside the heart to monitor its pulmonary artery. Implanted through a minimally invasive procedure, the sensor detects increases in pulmonary artery pressure, an early sign of worsening heart failure that can be detected before symptoms arise. Among the symptoms of advanced heart failure is shortness of breath, the kind of frightening experience that sends people racing to emergency rooms.
Once implanted, the device transmits daily pressure readings to a patient’s medical team, who can then proactively provide real-time, personalised feedback before symptoms worsen. The device has been shown in clinical trials to reduce hospital readmissions for advanced heart failure patients by up to 37 percent.
The new microchip technology is designed for advanced heart failure patients who have been hospitalised within the previous 12 months. The goal of Mount Sinai’s heart failure experts is to improve the quality of life in patients with heart failure and reduce the likelihood of hospital readmissions, a growing trend for this high-risk patient population which has become a national priority for the Centers for Medicare and Medicaid Services to reduce readmissions to curb growing healthcare costs.
‘This new device will enable heart failure patients to live more comfortably, easing their worries as we closely monitor them for the earliest signs of fluid retention, a major cause of the symptoms of breathlessness and tiredness heart failure patients experience,’ says Raymond Bietry, MD, Assistant Professor of Cardiology who was the first cardiologist at Mount Sinai to implant the device. Mount Sinai Hospital
Scientists have developed the first ultra-thin, flexible device that sticks to skin like a rub-on tattoo and can detect a person
St. Louis University scientists led by professor of pharmacological and physiological sciences Daniela Salvemini, Ph.D., discovered that drugs targeting the A3 adenosine receptor can ‘turn off’ pain signals in the spinal cord to provide relief from chronic pain.
Pain is the most common reason that people seek medical attention, but the available treatments–most commonly non-steroidal anti-inflammatory drugs (NSAIDs) and opioids–are not always successful at relieving pain in patients with chronic pain. For this reason, Salvemini and colleagues teamed up with researchers from the National Institutes of Health, the University of Arizona and two institutes in Quebec, Canada, to investigate a new target for treating chronic pain: the A3 adenosine receptor or A3AR.
In earlier studies, Salvemini’s laboratory demonstrated that two drugs which target the A3AR–IB-MECA and MRS5698–were effective in treating several models of chronic pain, including painful chemotherapy-induced neuropathy, metastatic cancer pain, and nerve injury. More recently, the group sought to uncover the mechanism of A3AR pain relief.
‘Chronic pain can result from the loss of regulatory mechanisms in the nervous system pathway that transmits pain,’ Salvemini said. ‘Adenosine acts as a regulatory signalling molecule in other areas of the nervous system, so we hypothesized that A3AR might also play a role in regulating pain signals during pain processing.’
Indeed, Salvemini and colleagues found that A3AR drugs not only relieved pain, but did so by activating an inhibitory transmitter system known as the gamma amino-butyric acid (GABA) system. In areas of the spinal cord and brain dedicated to pain processing, A3AR activation promoted GABA signalling by preventing the breakdown and removal of GABA from neuronal synapses.
‘In chronic pain, GABA signalling is often lost or diminished. Our A3AR drugs were able to restore GABA signalling in areas that process pain and ‘turn off’ the signals that maintain the pain state,’ Salvemini said.
With A3AR drugs demonstrating good safety profiles in clinical trials as anti-inflammatory and anti-cancer agents, Salvemini and colleagues are enthusiastic about the potential of these new drugs to treat chronic pain in patients. EurekAlert
A new study at the University of Wisconsin-Madison has linked two seemingly unrelated cancer treatments that are both now being tested in clinical trials.
One treatment is a vaccine that targets a structure on the outside of cancer cells, while the other is an altered enzyme that breaks apart RNA and causes the cell to commit suicide.
The new understanding could help both approaches, says UW-Madison professor of biochemistry Ronald Raines, who has long studied ribonucleases
Lightly stimulating the brain with electricity may improve short-term memory in people with schizophrenia, according to a new study by researchers at the Johns Hopkins University School of Medicine.
The procedure, known as transcranial direct current stimulation, involves placing sponge-covered electrodes on the head and passing a weak electrical current between them. It is widely regarded as safe, and the procedure is being studied as a treatment for depression and Alzheimer
Fluke Biomedical, the global leader in medical device quality assurance systems, launched Advantage Training, an online centre aimed at providing accessible training to the biomedical engineering community. The Advantage Training Centre features curriculum that covers the full spectrum of medical device preventive maintenance and quality assurance for biomedical and diagnostic imaging equipment. Training is available for all skills levels, and course topics range from introduction to basic terminology to advanced technical applications. The curriculum was developed by subject matter experts, including faculty from the Biomedical Engineering School at the University of Vermont.
Congenital heart experts from Spectrum Health Helen DeVos Children
For the patient, surgery involves extreme physical stress, and in older patients especially this can lead to disorders of consciousness or cognition. The acute confusional state known as delirium, however, can often be prevented by specialist nursing care after the operation, as Torsten Kratz and co-authors show. In their study delirium liaison nurses were employed to help care for surgical patients aged 70 years and over. In every patient, the risk of postoperative delirium was reduced compared to patients who received routine care.
Delirium is a frequent occurrence after surgery in older patients: among those aged 70 and older, up to one in two is affected. Besides age, risk factors for delirium include mental illness-such as dementia-and infections. The approach to care assessed by Torsten Kratz and co-authors focuses on patients’ cognitive problems. Specially trained nurses support patients to achieve early self-feeding, improved cognitive activity, and restorative sleep. In this study in a Berlin hospital, one patient in five receiving routine care suffered from postoperative delirium, whereas in the group receiving support from delirium liaison nurses, fewer than 1 in 20 developed cognitive disorders. The authors point out that the study was unable to identify which specific measures reduced the risk for delirium-that would require more studies in larger numbers of patients. EurekAlert
Kaiba was just a newborn when he turned blue because his little lungs weren
April 2024
The medical devices information portal connecting healthcare professionals to global vendors
Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@interhospi.com
PanGlobal Media IS not responsible for any error or omission that might occur in the electronic display of product or company data.
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlyCookie settingsWe may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.
Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.
We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.
We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.
.These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.
If you do not want us to track your visit to our site, you can disable this in your browser here:
.
We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page
Google Webfont Settings:
Google Maps Settings:
Google reCaptcha settings:
Vimeo and Youtube videos embedding:
.U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.
Privacy policy